[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"h-pylori\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:h-pylori":141},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,73,97,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280",false,"NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[26,27,28,29,30],"Helicobacter Pylori Infection","Dyspepsia","Peptic Ulcer Disease","Helicobacter Pylori","H Pylori",[32,33,34,35,36,37,27],"Helicobacter pylori","Helicobacter pylori eradication","Vonoprazan","Esomeprazole","Levofloxacin","Triple therapy","RECRUITING","2026-04-18",{"date":41,"type":42},"2026-04-22","ACTUAL",{"date":44,"type":20},"2026-04-15",{"date":46,"type":20},"2026-08-14",{"name":48,"class":49},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100564671","psychological-effects-of-h-pylori-associated-gastritis-100564671","NCT06632210","Psychological Effects of H Pylori Associated Gastritis","Psychological Effects of Helicopter Pylori Associated Gastritis in Patients Attending Assiut University Hospitals","Inclusion Criteria:\n\n1. all patients with H.Pylori associated gastritis that diagnosed by endoscopy.\n2. patients diagnosed by detection of H.Pylori Ag in stool\n\nExclusion Criteria:\n\n1. patients did not take antibiotics within last 2 weeks\n2. patients did not take PPI within last 1 month\n3. patients not with acute massive GITbleeding.\n4. patients without eradication of H.Pylor",{"count":59,"type":20},130,"OBSERVATIONAL","The goals of this study\n\n1. Explore association between psychological factors and Hpylori associated gastritis.\n2. Assess prevalence and severity of psychology symptoms among patients with H pylori associated gastritis and their effects on their life.\n3. Examine relation between demographic and clinical variables .\n4. Effect of eradication of H pylori on psychological status of patients.",[30],"NOT_YET_RECRUITING","2025-12-27",{"date":66,"type":42},"2026-01-02",{"date":68,"type":20},"2026-03-22",{"date":70,"type":20},"2026-12-22",{"name":72,"class":49},"Assiut University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100605029","associating-gastric-infection-with-autoimmune-flare-severity-in-an-egyptians-100605029","NCT07157202","Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians","Association Between Helicobacter Pylori Infection and Disease Activity in Patients With Systemic Lupus Erythematosus (SLE)","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years) with a confirmed diagnosis of SLE according to the American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria.\n\nPatients who provide written informed consent to participate in the study. Patients who have not received antibiotics or proton pump inhibitors (PPIs) in the four weeks\n\nExclusion Criteria:\n\n* Patients with a history of gastric surgery or known gastrointestinal malignancy.\n\n  * Patients currently receiving immunosuppressive therapy for conditions other than SLE.\n  * Patients with coexisting autoimmune diseases other than SLE.\n  * Pregnant or lactating women.\n  * Patients with active infections (other than H. pylori) at the time of enrollment.",{"count":81,"type":20},115,"A cross-sectional, observational study aims to evaluate the relationship between Helicobacter pylori infection and disease activity in patients diagnosed with systemic lupus erythematosus (SLE), using a combination of structured patient interviews, standardized disease assessments, and laboratory detection of H. pylori by stool antigen testing .",[84,85],"H. Pylori","SLE - Systemic Lupus Erythematosus",[87,88],"SLE","H. pylori infection","2025-08-28",{"date":91,"type":42},"2025-09-05",{"date":93,"type":20},"2026-08-30",{"date":95,"type":20},"2027-12-30",{"name":72,"class":49},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100596083","phase-4-comparison-of-omeprazole-vs-vonoprazon-in-treatment-of-h-pylori-infection-100596083","NCT07040839","Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* All patients who tested positive on stool antigen\n\nExclusion Criteria:\n\n* patients under 12 years old.\n* Patients who have penicillin allergy.\n* Patients who have underlying dysrhythmia forbidding the use of macrolide -. Patient who have hypersensitivity to any of these antibiotics or proton pump inhibitors.",true,"12 Years",{"count":107,"type":20},128,[23],"Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations.\n\nThis study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.",[30],[112,113,114],"omeprazole","vonoprazon","proton pump inhibitors","2025-06-26",{"date":117,"type":42},"2025-06-27",{"date":119,"type":20},"2025-07",{"date":121,"type":20},"2026-02",{"name":123,"class":49},"Rehman Medical Institute - RMI",1,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":104,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100537236","h-pylori-screen-and-treat-study-in-a-population-of-young-adults-100537236","NCT06275204","H. Pylori Screen-and-treat Study in a Population of Young Adults","Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults","Inclusion Criteria:\n\n* Young adults (generally 30 - 34 years of age)\n\nExclusion Criteria:\n\n* Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team)\n* Previously treated H. pylori infection\n* History of partial or total gastric resection due to benign or malign lesions","30 Years","34 Years",{"count":135,"type":20},6800,"Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia.\n\nMain goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up.\n\nPatients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.",[138,139,140,141],"Gastric Cancer","H Pylori Infection","H Pylori Eradication","H-pylori",[143,144,145,146],"H. pylori","gastric cancer","eradication therapy","screening","2024-03-03",{"date":149,"type":42},"2024-03-05",{"date":151,"type":20},"2024-03-04",{"date":153,"type":20},"2026-12-01",{"name":155,"class":49},"University of Latvia",7]